Jump to content
Advertisement

Advertisement

IBS News

Showing topics posted by Health Reporter and posted in for the last 365 days.

This stream auto-updates     

  1. Today
  2. Google-Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS - MD Linx http://dlvr.it/RXpDqT (Feed generated with FetchRSS) View the full article
  3. Yesterday
  4. Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS MD Linx In view of the fact that although irritable bowel syndrome ( IBS) is more prevalent among women, less is known about the role of hormonal changes and menopause in IBS, researchers sought to examine differences in gastrointestinal (GI) and psychological symptoms between pre‐ and postmenopausal women with IBS relative to age‐matched men with IBS. Patients with Rome‐positive IBS have been identified. Premenopausal women were < 45 years of age with regular menses and postmenopausal women were ≥ 45 years with no menses for at least 1 year. Younger men were < 45 years of age and older men were ≥ 45 years of age. Participants in the study were 190 premenopausal women (mean age 30.25 years), 52 postmenopausal women (mean age 54.38 years), 190 men < 45 years (mean age 30.45 years), and 52 men ≥ 45 years (mean age 53.37 years). Compared with premenopausal women, postmenopausal IBS women had greater severity of IBS symptoms and worse physical health‐related quality of life. No discrepancies were noted between age‐matched older and younger IBS men. View the full article
  5. Postcolonoscopy Antibiotics Linked With IBS Medscape Antibiotic exposure within 14 days after screening colonoscopy may increase risk of irritable bowel syndrome (IBS), based on a retrospective analysis of more than 400,000 individuals. Antibiotic use in the 2 weeks leading up to colonoscopy also trended toward an association with IBS, reported lead author Ravy Vajravelu, MD, of University of Pennsylvania, Philadelphia, and colleagues. "Laboratory studies in mice have demonstrated that colon cleansing in conjunction with systemic antibiotic use can cause persistent intestinal dysbiosis," the investigators wrote in an abstract released as part of the annual Digestive Disease Week®, which was canceled because of COVID-19. "Because perturbation of the gut microbiome is thought to be a trigger for the development of IBS, we sought to assess whether humans who undergo bowel cleanse for colonoscopy in conjunction with antibiotic exposure develop new-onset IBS or IBS-related symptoms." According to Dr. Vajravelu, previous human studies have shown that bowel cleansing or antibiotics can alter the baseline gut microbiome, but no previous human research explored the impact of both triggers at once. View the full article
  6. Mayo Clinic joins Biomerica's InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial GlobeNewswire Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods, that when removed from the diet, alleviate an individual's IBS symptoms Approximately 45 million Americans suffer from IBS1 IRVINE, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced they have signed definitive agreements with Mayo Clinic to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. Mayo Clinic is joining Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist and the University of Michigan as primary enrollment centers for this study. Mayo Clinic can now begin enrollment of patients in this trial. Biomerica has added several new, large medical centers and groups to assist with accelerating completion of the endpoint trial and to participate in the subsequent pivotal trial needed for final FDA clearance. Biomerica continues to add leading gastrointestinal ("GI") physicians operating in world-renowned centers to the InFoods® IBS clinical study, who are potential users and advocates for this product once cleared by the FDA. Biomerica also announced today that the Japanese Patent Office has issued Biomerica’ s first Japanese patent pertaining to the Company’s InFoods® family of products that allow for a revolutionary new treatment option for patients suffering from IBS and several other disease states. Specifically, this patent (JP,6681907,B) contains numerous claims that broadly cover a product that enables physicians to identify patient-specific foods (e.g. pork, milk, shrimp, broccoli, chickpeas, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. It is estimated that about 19 million people in Japan suffer from IBS. It is estimated that over 45 million Americans suffer from IBS and the symptoms are often triggered by consumption of specific foods (which are unique in each sufferer). The total cost (direct + indirect) of IBS has been estimated at $30 billion annually in the United States. IBS is a common condition that can substantially impair physical and mental well-being of a patient and a person’s ability to function both at home and in the workplace. A clinical lab version of the product is being used in this clinical trial. However, the Company is also developing InFoods® IBS DGT as a point-of-care product that allows physicians to perform the test in-office using a finger stick blood sample. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for the InFoods® IBS products. Market research conducted by a leading, independent pharmaceutical marketing research firm, determined that seventy percent (70%) of physicians surveyed would utilize the InFoods® DGT without reimbursement and over 90% would utilize it with reimbursement. Importantly, the InFoods® DGT can be used without or in conjunction with current pharmaceuticals to potentially improve patient outcomes. Since the InFoods® product is a diagnostic-guided therapy and not a drug, it has no drug-type side effects. The clinical trials are randomized, double-blinded, and placebo-controlled. Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, has completed its enrollment of patients for this endpoint study but will continue to participate in the final pivotal trial once that commences. This clinical endpoint trial is expected to be completed in approximately 6 months. However, due to the novel coronavirus’ impact on the U.S.’s healthcare system, it may take longer. If all goes as expected, Biomerica plans to commence the final pivotal trial several months thereafter, which is needed for submission to the FDA for final clearance. The endpoint trial stratifies enrollment by the three main IBS subclasses (IBS-Constipation, IBS-Diarrhea and IBS-Mixed). There is currently no FDA cleared therapy for IBS-Mixed. The study design has already received a non-significant risk determination from FDA. Zackary Irani, Chief Executive Officer of Biomerica, commented: “We are excited to have Mayo Clinic join the InFoods® IBS trial. IBS patients who desperately seek symptom relief will be the beneficiaries of this revolutionary disruptive technology. Also, we are pleased to have additional countries issue patents with broad claims that acknowledge the novel and innovative attributes of this technology platform that can be used to help patients that suffer from IBS and many other diseases.” View the full article
  7. Last week
  8. Related ArticlesSaccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Curr Microbiol. 2020 May 29;: Authors: Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M, Folwarski M, Makarewicz W Abstract The yeast Saccharomyces boulardii CNCM I-745 is a unique, non-bacterial microorganism classified as a probiotic agent. In this review article, at first, we briefly summarized the mechanisms responsible for its probiotic properties, e.g. adhesion to and elimination of enteropathogenic microorganisms and their toxins; extracellular cleavage of pathogens' virulent factors; trophic and anti-inflammatory effects on the intestinal mucosa. The efficacy of S. boulardii administration was tested in variety of human diseases. We discussed the results of S. boulardii CNCM I-745 use in the treatment or prevention of Helicobacter pylori infections, diarrhoea (Clostridium difficile infections, antibiotic-associated diarrhoea, and traveller's diarrhoea), inflammatory bowel diseases, irritable bowel syndrome, candidiasis, dyslipidemia, and small intestine bacterial overgrowth in patients with multiple sclerosis. In case of limited number of studies regarding this strain, we also presented studies demonstrating properties and efficacy of other strains of S. boulardii. Administration of S. boulardii CNCMI I-745 during antibiotic therapy has certain advantage over bacterial probiotics, because-due to its fungal natural properties-it is intrinsically resistant to the antibiotics and cannot promote the spread of antimicrobial resistance. Even though cases of fungemia following S. boulardii CNCM I-745 administration were reported, it should be treated as a widely available and safe probiotic strain. PMID: 32472262 [PubMed - as supplied by publisher] View the full article
  9. 'Life goes on after garlic, believe me.' A great article by @BBCFood discussing the ins and outs of the #lowFODMAP diet. http://ow.ly/MxCq50zQWbC (Feed generated with FetchRSS) View the full article
  10. Related ArticlesRisk for Irritable Bowel Syndrome in Patients with Helicobacter Pylori Infection: A Nationwide Population-Based Study Cohort Study in Taiwan. Int J Environ Res Public Health. 2020 May 25;17(10): Authors: Liang CM, Hsu CH, Chung CH, Chen CY, Wang LY, Hsu SD, Chang PK, Hong ZJ, Chien WC, Hu JM Abstract BACKGROUND: The association between Helicobacter pylori (H. pylori) infection and the risk of developing irritable bowel syndrome (IBS) has yet to be investigated; thus, we conducted this nationwide cohort study to examine the association in patients from Taiwan. METHODS: A total of approximately 2669 individuals with newly diagnosed H. pylori infection and 10,676 age- and sex-matched patients without a diagnosis of H. pylori infection from 2000 to 2013 were identified from Taiwan's National Health Insurance Research Database. The Kaplan-Meier method was used to determine the cumulative incidence of H. pylori infection in each cohort. Whether the patient underwent H. pylori eradication therapy was also determined. RESULTS: The cumulative incidence of IBS was higher in the H. pylori-infected cohort than in the comparison cohort (log-rank test, p < 0.001). After adjustment for potential confounders, H. pylori infection was associated with a significantly increased risk of IBS (adjusted hazard ratio (aHR) 3.108, p < 0.001). In addition, the H. pylori-infected cohort who did not receive eradication therapy had a higher risk of IBS than the non-H. pylori-infected cohort (adjusted HR 4.16, p < 0.001). The H. pylori-infected cohort who received eradication therapy had a lower risk of IBS than the comparison cohort (adjusted HR 0.464, p = 0.037). CONCLUSIONS: Based on a retrospective follow-up, nationwide study in Taiwan, H. pylori infection was associated with an increased risk of IBS; however, aggressive H. pylori infection eradication therapy can also reduce the risk of IBS. Further underlying biological mechanistic research is needed. PMID: 32466223 [PubMed - in process] View the full article
  11. Related ArticlesFecal Urgency: Clinical and Manometric Characteristics in Patients With and Without Diarrhea. Dig Dis Sci. 2020 May 28;: Authors: Rangan V, Nee J, Singh P, Ballou S, Iturrino J, Hirsch W, Lembo A Abstract BACKGROUND: Fecal urgency is classically associated with diarrhea, but is also common in individuals with normal bowel habits or constipation. Its etiology, particularly in non-diarrhea individuals, is unclear. METHODS: We examined data from 368 individuals with and without diarrhea who underwent three-dimensional high-resolution anorectal manometry and balloon expulsion test. All patients completed the Rome III constipation module and the pelvic floor distress inventory (PDFI-20) survey. Patients were considered to have fecal urgency if they reported being bothered "moderately" or "quite a bit" by it in the past 3 months. RESULTS: A total of 103 patients (28.0%) met our definition of fecal urgency. These patients were significantly more likely to meet criteria for irritable bowel syndrome and to report fecal incontinence, urinary incontinence, and diarrhea. Fecal urgency was associated with rectal hypersensitivity in those with diarrhea, but not in those without diarrhea. Fecal urgency was associated with urinary urge incontinence in those without diarrhea, but not those with diarrhea. CONCLUSIONS: In patients with diarrhea, fecal urgency is associated with rectal hypersensitivity, whereas in patients without diarrhea, fecal urgency is associated with urinary urge incontinence. This suggests that fecal urgency has different pathophysiological mechanisms in patients with different underlying bowel habits. PMID: 32468228 [PubMed - as supplied by publisher] View the full article
  12. Related ArticlesUndiagnosed Celiac Disease In Patients Presenting With Irritable Bowel Syndrome Symptoms. J Ayub Med Coll Abbottabad. 2020 Jan- Mar;32(1):18-23 Authors: Khayyat YM Abstract BACKGROUND: Irritable bowel syndrome (IBS) is a common clinical condition that is often diagnosed based on a set of clinical criteria. Celiac disease (CD) has a similar symptom. The study aims to estimate the prevalence of undiagnosed celiac disease (CD) in patients with criteria-positive IBS and compare with healthy control. METHODS: A Case control study conducted from August 2013 to July 2016. For the control group with negative ROME 3 criteria for IBS provided serum total immunoglobulin (IgA) level and serum tissue transglutaminase antibody (tTG IgA). The case group with positive criteria interviewed, examined, competed ROME 3 questionnaire and provided blood sample for haematology, biochemistry, and serum tTG IgA and IgG. Positive for CD invited for upper endoscopy and duodenal biopsy for evaluation of pathological involvement using the modified Marsh classification. RESULTS: Three controls (1.47%) and 21 cases (6.9%) had positive serology for CD. A statistically significant association found between serum tTG positivity and IBS and IBS-diarrhoea subtypes. No correlation was found between tTG positivity and age and sex of the case group. CONCLUSIONS: Celiac disease is common in IBS patients especially those with criteria-positive diagnosis. Serology screening for CD is helpful in IBS and IBS-D patients. PMID: 32468748 [PubMed - in process] View the full article
  13. Challenges of the low FODMAP diet for managing irritable bowel syndrome and approaches to their minimisation and mitigation. Proc Nutr Soc. 2020 May 29;:1-10 Authors: Wilson B, Cox SR, Whelan K Abstract Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) is clinically effective and a commonly utilised approach in the management of functional symptoms in irritable bowel syndrome. Despite this, the low FODMAP diet has a number of challenges: it can alter the gut microbiota; impact nutrient intake and diet quality; is complex to understand; requires the patient to be adequately supported to follow the diet accurately and safely; and lastly, not all patients respond to the diet. The current review highlights the evidence for the clinical effectiveness of the low FODMAP diet, but focusses on the challenges associated with the diet to the patient, health professionals and the wider healthcare service. Finally, the review discusses research findings and practical guidance for how these challenges can be minimised and mitigated. The low FODMAP diet is a useful management strategy for irritable bowel syndrome, with data from clinical trials suggesting a 50-80% response rate, and when administered appropriately, the challenges to implementing the diet can be overcome so that these outcomes can be realised effectively and safely in clinical practice. PMID: 32468985 [PubMed - as supplied by publisher] View the full article
  14. Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS. Neurogastroenterol Motil. 2020 May 29;:e13913 Authors: Lenhart A, Naliboff B, Shih W, Gupta A, Tillisch K, Liu C, Mayer EA, Chang L Abstract BACKGROUND: Although irritable bowel syndrome (IBS) is more common in women, little is known about the role of hormonal changes and menopause in IBS. This study aimed to evaluate for differences in gastrointestinal (GI) and psychological symptoms between pre- and postmenopausal women with IBS compared to age-matched men with IBS. METHODS: Patients with Rome-positive IBS were identified. Premenopausal women were <45 years of age with regular menses. Postmenopausal women were ≥45 years without menses for at least 1 year. Younger men were <45 years, and older men were ≥45 years. Questionnaires measured severity of IBS symptoms, somatic symptoms, health-related quality of life (HRQOL), and psychological symptoms. Multivariable linear or logistic regressions evaluating relationships between age and sex were performed. KEY RESULTS: 190 premenopausal women (mean age 30.25 years), 52 postmenopausal women (mean age 54.38 years), 190 men <45 years (mean age 30.45 years), and 52 men ≥45 years (mean age 53.37 years) were included. Postmenopausal IBS women had greater severity of IBS symptoms (P = .003) and worse physical HRQOL (P = .048) compared to premenopausal women. No differences were observed between age-matched older and younger IBS men. Constipation increased with age for both sexes but was the principal IBS subtype in women only. CONCLUSIONS AND INFERENCES: Postmenopausal women with IBS have more severe IBS symptoms than premenopausal women, while no comparable age-related changes were seen in IBS men. The modulatory effect of female sex hormones on brain-gut interactions which affect visceral perception and GI function likely contributes to these findings. PMID: 32469130 [PubMed - as supplied by publisher] View the full article
  15. The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study. PLoS One. 2020;15(5):e0234089 Authors: Hamaguchi T, Tayama J, Suzuki M, Nakaya N, Takizawa H, Koizumi K, Amano Y, Kanazawa M, Fukudo S Abstract Irritable bowel syndrome (IBS) is a common bowel disorder that manifests as unexplained abdominal pain or discomfort and bowel habit changes in the form of diarrhea, constipation, or alternating patterns of the two. Some evidences demonstrate that increased physical activity improves IBS symptoms. Hence, daily exercise is recommended in these patients. In this study, we aimed to investigate the relationship between physical activity and gastrointestinal symptoms in 101 university students (female = 78) with IBS. Participants were examined by Gastrointestinal Symptoms Rating Scale (GSRS), and gait steps were measured for 1 week using a pedometer. The association between the GSRS score and pedometer counts was determined by ordinal logistic modeling analysis. The ordinal logistic regression model for GSRS and locomotor activity showed a significant stepwise fit (z = -3.05, p = 0.002). The logistic curve separated GSRS score of 5 points (moderately severe discomfort) from 2 points (minor discomfort) by locomotor activity. The probability for daily locomotor activity to discriminate between 5 and 4 points of GSRS (i.e., likely to have reverse symptoms) decreased in accordance with increment of steps per day: 78% probability for 4000 steps, 70% probability for 6000 steps, 59% probability for 8000 steps, and 48% probability for 10000 steps. This study demonstrated that the severity of GSRS is associated with the amount of walking in younger people with IBS. These results may be used as a measure to determine the daily step count to reduce the severity of gastrointestinal symptoms in individuals with IBS. PMID: 32470098 [PubMed - as supplied by publisher] View the full article
  16. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacol Res. 2020 May 26;:104936 Authors: Li Y, Hong G, Yang M, Li G, Jin Y, Xiong H, Qian W, Hou X Abstract OBJECTIVE: Rifaximin for treating diarrhea-predominant irritable bowel syndrome (IBS-D) by regulating intestinal microbiota has been studied and recommended. In this study, we tried to investigate the effect of rifaximin on different components of intestinal microbiota and explore which component of gut microbiota can predict the efficacy of rifaximin in IBS-D. METHODS: Healthy controls (HC) and IBS-D patients meeting the Rome III criteria were recruited, and IBS-D patients were orally administered 400 mg rifaximin three times daily for 2 weeks. Subjects were tested for small intestinal bacterial overgrowth (SIBO), their symptoms were recorded, and fecal and rectal mucosal samples were collected before and after treatment. Fecal and rectal mucosal bacterial data were obtained via 16S rRNA sequencing, and fecal fungal data were obtained via ITS2 sequencing. RESULTS: IBS-D patients were divided into two subgroups based on fecal bacterial composition, IBS1 (patients whose fecal bacterial composition were different from HC) and IBS0 (patients whose fecal bacterial profiles were similar to HC). Rifaximin increased fecal Bifidobacterium and decreased E. coli and Enterobacter in IBS1 patients. Although rectal mucosal bacteria and fecal fungi were not significantly altered in all patients after rifaximin intervention, rifaximin enhanced the connections among fecal bacteria, mucosal bacteria and fecal fungi in IBS1 patients. Compared with IBS0, we surprisingly found rifaximin ameliorated abdominal symptoms of IBS1 much better. Receiver operating curve analysis revealed patients whose fecal microbial dysbiosis indices (MDI) were higher than -3.006 could be diagnosed as IBS1. CONCLUSION: Fecal bacterial dysbiosis could be a biomarker for rifaximin treatment for IBS-D. PMID: 32470562 [PubMed - as supplied by publisher] View the full article
  17. Treat your family this weekend to a decadent brunch with this PB&J Baked French Toast 🍓🥜😋 - featuring the #MonashFODMAPCertified LowFOD™ loaf from @COBSBread The Cobs LowFOD™ loaf is available in 🇨🇦 & 🇺🇸 ✨ Recipe link: http://ow.ly/WA1Q50zTbci (Feed generated with FetchRSS) View the full article
  18. I often hear that it’s expensive to follow the low FODMAP diet, so here are some simple tips on how to save. #lowfodmap #fodmap #fodmapdiet #foodbudget https://www.lowfodmapdiets.com/7-tips-save-low-fodmap-diet/ (Feed generated with FetchRSS) View the full article
  19. The relationship between acne vulgaris and irritable bowel syndrome: A preliminary study. J Cosmet Dermatol. 2020 May 28;: Authors: Demirbaş A, Elmas ÖF Abstract BACKGROUND: Irritable bowel syndrome (IBS) is a functional gastrointestinal disease characterized by chronic abdominal pain and changes in bowel movements without underlying organic pathology. Many skin diseases have been reported to be more common in individuals with functional bowel diseases. AIMS: In this study, we aimed to investigate a possible relationship between acne vulgaris (AV) and IBS. PATIENTS/METHODS: This prospective controlled study included patients with AV and healthy volunteers. All the subjects were evaluated in terms of the presence of IBS. The diagnosis of IBS was made based on the ROME IV diagnostic criteria. The clinical severity of AV was calculated using the global acne grading system (GAGS). RESULTS: A total of 300 patients with acne vulgaris and 300 age and gender-matched healthy controls were included in the study. The majority of the patients were female (n = 175, 58.3%). The mean ages of the patients and controls were 20.22 ± 5.24 years and 20.49 ± 5.36 years, respectively. A total of 183 patients (61.0%) and 84 (28.0%) controls were diagnosed with IBS based on the Rome IV diagnostic criteria. The frequency of IBS was statistically significantly higher in the patient group than in the control group. (P = .001). There was also statistically significant relationship between the GAGS scores and IBS diagnosis (P = .001), abnormal stool form (P = .001), abdominal distention (P = .001), and feeling of incomplete evacuation (P = .001). CONCLUSION: Our study showed that IBS is significantly more common in patients with AV than in healthy controls. Additionally, GAGS scores were higher in patients diagnosed with IBS. To the best of our knowledge, this is the first study focusing on the subject. PMID: 32463985 [PubMed - as supplied by publisher] View the full article
  20. The Bacterial Connection between the Oral Cavity and the Gut Diseases. J Dent Res. 2020 May 28;:22034520924633 Authors: Kitamoto S, Nagao-Kitamoto H, Hein R, Schmidt TM, Kamada N Abstract More than 100 trillion symbiotic microorganisms constitutively colonize throughout the human body, including the oral cavity, the skin, and the gastrointestinal tract. The oral cavity harbors one of the most diverse and abundant microbial communities within the human body, second to the community that resides in the gastrointestinal tract, and is composed of >770 bacterial species. Advances in sequencing technologies help define the precise microbial landscape in our bodies. Environmental and functional differences render the composition of resident microbiota largely distinct between the mouth and the gut and lead to the development of unique microbial ecosystems in the 2 mucosal sites. However, it is apparent that there may be a microbial connection between these 2 mucosal sites in the context of disease pathogenesis. Accumulating evidence indicates that resident oral bacteria can translocate to the gastrointestinal tract through hematogenous and enteral routes. The dissemination of oral microbes to the gut may exacerbate various gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, and colorectal cancer. However, the precise role that oral microbes play in the extraoral organs, including the gut, remains elusive. Here, we review the recent findings on the dissemination of oral bacteria to the gastrointestinal tract and their possible contribution to the pathogenesis of gastrointestinal diseases. Although little is known about the mechanisms of ectopic colonization of the gut by oral bacteria, we also discuss the potential factors that allow the oral bacteria to colonize the gut. PMID: 32464078 [PubMed - as supplied by publisher] View the full article
  21. Interested in learning about gut directed hypnosis for #IBS -learn from top expert @DrPalssonUNC on Facebook w/ @RomeFoundation. Details below! 👇🏼 https://twitter.com/ddrossman/status/1266001540218785794 (Feed generated with FetchRSS) View the full article
  22. Four of 10 adults worldwide have functional gastrointestinal disorders Medical Xpress For every 10 adults in the world, four suffer from functional gastrointestinal disorders of varying severity. This is shown by a study of more than 73,000 people in 33 countries. University of Gothenburg scientists are among those now presenting these results. Functional gastrointestinal disorders, FGIDs, is a collective term for chronic disorders in the gastrointestinal tract, with severe symptoms, for which clear explanations or connections with objective findings from routine investigations are lacking. View the full article
  23. Related ArticlesKnowledge and practices of primary care physicians or general practitioners treating post-infectious Irritable Bowel Syndrome. BMC Gastroenterol. 2020 May 25;20(1):159 Authors: Austhof E, Schaefer K, Faulkner J, Bach L, Riddle M, Pogreba-Brown K Abstract BACKGROUND: Post-infectious Irritable Bowel Syndrome (PI-IBS) is a functional bowel disorder which has significant impacts to a patient's quality of life. No IBS-specific biomarker or treatment regimen for PI-IBS currently exists, therefore understanding practice patterns and variance is of interest. METHODS: This online survey of primary care physicians and general practitioners in the USA aimed to understand the knowledge and treatment of PI-IBS within the physician's current practice. Summary statistics are provided with a commentary on implications for practices and treatment of PI-IBS. RESULTS: Most physician survey respondents (n = 50) were aware of PI-IBS, but less than half discussed this condition as a possible outcome in their patients with a recent gastrointestinal infection. Most physicians indicated that they would treat the patients themselves with a focus on managing IBS through different treatment modalities based on severity. Treatment for PI-IBS followed IBS recommendations, but most physicians also prescribed a probiotic for therapy. Physicians estimated that 4 out of 10 patients who develop PI-IBS will have life-long symptoms and described significant impacts to their patient's quality of life. Additionally, physicians estimated a significant financial burden for PI-IBS patients, ranging from $100-1000 (USD) over the course of their illness. Most physicians agreed that they would use a risk score to predict the probability of their patients developing PI-IBS, if available. CONCLUSIONS: While this survey is limited due to sample size, physician knowledge and treatment of PI-IBS was consistent across respondents. Overall, the physicians identified significant impacts to patient's quality of life due to PI-IBS. PMID: 32450813 [PubMed - in process] View the full article
  24. Related ArticlesThe antibacterial activity of Berberis heteropoda Schrenk and its effect on irritable bowel syndrome in rats. Chin J Nat Med. 2020 May;18(5):356-368 Authors: Li L, Zhu HM, Yan Q, Li SY, Li F Abstract The dried roots of Berberis heteropoda Schrenk have traditionally been used to treat acute gastroenteritis and dysentery. The aim of this study was to confirm the antibacterial activity of an extract of Berberis heteropoda Schrenk rootin vitro and its therapeutic effects on rats with diarrhea-predominant irritable bowel syndrome (D-IBS) in vivo, as well as to identify the related signaling pathways. A water extract of Berberis heteropoda Schrenk root (BHS) inhibited the growth of S. aureus, E. coli, P. aeruginosa and S. faecalis. BHS potentially damaged the structure of the bacterial cell membrane and decreased the activity of some membranous enzymes, eventually killing the S. aureus, E. coli, P. aeruginosa and S. faecalis bacteria. Oral administration of BHS (low, middle and high dose group, L, M and H) significantly alleviated the abdominal pain, diarrhea, and depression-like symptoms of D-IBS rats, and the efficacy index ranged from 30% to 60%, indicating that the BHS treatment was effective. BHS (L, M and H) alleviated the abnormal pathological changes in the brain, as evidenced by HE staining. The expression of CHAT, 5-HT, C-FOS and CGRP was reduced by the BHS treatment (L, M and H). Our findings provide novel insights into the use of the natural product BHS to inhibit pathogenic bacteria by destroying the bacterial structure, indicating that BHS possesses certain biological activities. Furthermore, BHS has the potential to alleviate diarrhea, abdominal pain and depression-like behaviors in D-IBS rats by regulating the brain-gut peptide levels. PMID: 32451093 [PubMed - in process] View the full article
  25. Related ArticlesIrritable bowel syndrome frequency and related factors in hemodialysis patients. Hemodial Int. 2020 May 25;: Authors: Özkul D, Güney İ, Saçkan F, Coşkun Yavuz Y, Yilmaz N, Tonbul HZ Abstract INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disease that is common in society, does not threaten life, impairs quality of life, and causes serious economic losses. Gastrointestinal system complaints and especially IBS are common in patients with chronic kidney disease. It has also been shown that psychiatric diseases are more common in patients with IBS. In this study, we aimed to determine the frequency of IBS in hemodialysis patients and to investigate the factors associated with IBS. METHODS: In this cross-sectional study, the questionnaire prepared to evaluate depression, anxiety, and abdominal pain was administered face-to-face to 686 patients by the same researcher in seven dialysis centers; 404 patients without exclusion criteria were included in the study. The diagnosis of IBS was made according to Rome IV criteria. A multivariate logistic regression model was used to identify factors that are significantly related to IBS. FINDINGS: In 69 (17.1%) of the patients included in the study, symptoms were consistent with IBS. Binominal logistic regression analysis was performed to evaluate the effect of age, dialysis duration, diabetes, proton pump inhibitor, non-steroidal anti-inflammatory drugs, calcium acetate use, Hamilton depression and anxiety scores associated with IBS in the presence of IBS of the participants. The logistic regression model was statistically significant, χ2 (3) = 69.748, P < 0.001. Independent risk factors for IBS in hemodialysis patients were determined as anxiety, long-term dialysis treatment, and using calcium acetate as a phosphorus binder. DISCUSSION: In hemodialysis patients, IBS occurs approximately twice as often as in a healthy population. Independent risk factors for IBS in hemodialysis patients are anxiety, long-term dialysis treatment, and using calcium acetate as a phosphorus binder. PMID: 32452111 [PubMed - as supplied by publisher] View the full article
  26. RT @drjshapiro: @TuesdayNightIBS @john_damianos @DrvanTilburg @DrPalssonUNC @RomeFoundation @miguelsaps The AAP, ACP, and AAFP published the 3rd version of guidelines in 2018 with 6 Core Elements of Transition. It is supposed to start to standardize the process, but there's a long way to go. https://pediatrics.aappublications.org/content/142/5/e20182587 Worth a read for all providers! @GotTransition2 (Feed generated with FetchRSS) View the full article
  27. Earlier
  28. Risk factors for adverse events in patients with chronic constipation following lubiprostone administration MD Linx Since lubiprostone is an effective treatment of chronic constipation (CC), however, as with other stimulant or osmotic laxatives, adverse events (AEs) can make it difficult to continue treatment, researchers sought to examines AE risk factors associated with lubiprostone. All 1,338 Japanese individuals with CC treated at the hospital from October 2013 to July 2017 were retrospectively analyzed. Constipation was diagnosed to all patients, as defined by the Roma III criteria. No serious AEs have been associated with the study drug. Diarrhea (6.1%) and nausea (4.2%) were the AEs reported by > 1% of patients overall. Patient age of 65 years or more were factors associated with higher incidence of diarrhea. Factors associated with greater risk of nausea included female gender, and a patient complaining of abdominal pain and fullness was the chief complaint. Understanding risk factors for AE may help avoid unnecessary AEs and promote more efficient care. View the full article
  29. Sex Bias Persists in Pain Research Pain News Network It’s long been known that women are more likely than men to have chronic pain conditions such as fibromyalgia, rheumatoid arthritis, irritable bowel syndrome (IBS) and migraine. Women are also more likely to feel more severe, recurring and longer lasting pain. Why then are women less likely to receive pain treatment? And why are some treatments less effective for women? View the full article
  1. Load more activity
×
×
  • Create New...